CellChorus expands commercial and R&D facilities in Houston

PRESS RELEASE

HOUSTON, Texas — October 6, 2021 — CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how thousands of individual cells perform over time, today announced that it has expanded its commercial and R&D facilities in Houston.

“Demand for access to our platform was exceeding our capacity,” said Daniel Meyer, CEO of CellChorus. “The new facilities enable us to expand the number of innovators that rely on the TIMING platform to develop and deliver novel therapies."

CellChorus launched with early access customers in immuno-oncology. The company has recently expanded its activities across a range of indications such as infectious diseases and auto-immune disorders. The expansion will support further growth across indications, therapy types, and use cases.

The new facilities are located in the UH Technology Bridge and include cell culture and microscopy laboratories. The location allows CellChorus to maintain proximity to institutions such as Baylor College of Medicine, MD Anderson Cancer Center, Texas Medical Center, and the University of Houston.

About CellChorus

CellChorus is the leader in applying artificial intelligence to visually evaluate how thousands of individual cells, such as T cells and NK cells, perform over time. The company applies Time lapse Imaging Microscopy in Nanowell Grids (TIMING™) with neural network-based detection to identify cells and evaluate their activity, including how they move, activate, kill and survive. The patent-protected CellChorus platform can link TIMING data and insights with information from other analysis modalities such as single-cell RNA sequencing and flow cytometry to provide a comprehensive understanding of cellular function, state and phenotype for the life sciences industry. Please visit www.cellchorus.com for more information.

Company Contact:
Daniel Meyer
Chief Executive Officer
CellChorus Inc.
TIMING@cellchorus.com

SOURCE CellChorus Inc.